Sera Prognostics (SERA) announced that it has commenced a proposed underwritten public offering of its Class A common stock and, in lieu of

The firm plans to use the proceeds to support commercial expansion in the US and EU, and for research, potential regulatory submissions, and general corporate purposes.

SALT LAKE CITY - Sera Prognostics, Inc. (SERA), a company specializing in pregnancy biomarker information, has initiated a public offering of its Class A common stock and pre-funded warrants. The offering includes an additional option for underwriters to purchase up to 15% more shares.